Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 17, 2007

Dara Gains Access to Bayer Metabolic Disease IP

  • Bayer Pharmaceuticals granted Dara BioSciences exclusive, worldwide rights to patents and compounds for the treatment of metabolic diseases.

    In particular, the deal covers candidates for the treatment of type 2 diabetes and dyslipidemia. Lead compounds are in later preclinical development, according to the firms.

    Dara BioSciences will develop and commercialize products. Bayer will receive an upfront payment, milestone fees, and royalties. In addition, Bayer has certain rights to commercialize products emanating from this program.

    “DARA BioSciences' licensing-in of the Bayer technology demonstrates our commitment to exploring new alternatives in the treatment of metabolic diseases including diabetes,” states Richard A. Franco Sr., president and CEO. “This transaction also demonstrates our continuing success in executing our strategy to identify new opportunities in order to expand and diversify our product portfolio. We look forward to the opportunity to work with Bayer.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »